SCHEMBL15849062

SCHEMBL15849062

COc1ccc(-n2cccn2)nc1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.61
MEN1 O00255 1/20 0.61
CYP1A2 P05177 2/20 0.56
CYP2C19 P33261 2/20 0.56
KDM4E B2RXH2 6/20 0.55
HPGD P15428 2/20 0.55
NPSR1 Q6W5P4 1/20 0.55
LMNA P02545 1/20 0.53
CYP2D6 P10635 1/20 0.50
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
ALDH1A1 P00352 2/20 0.45
RXFP1 Q9HBX9 1/20 0.45
GLA P06280 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
EGLN1 Q9GZT9 3/20 0.42
CHRNA7 P36544 1/20 0.41
KCNH2 Q12809 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13075376 0.83 LMNA (0.53) KMT2AMEN1CYP1A2CYP2C19KDM4E
SCHEMBL24922128 0.83 KMT2A (0.52) KMT2AMEN1CYP1A2CYP2C19KDM4E
SCHEMBL12896223 0.83 KMT2A (0.51) KMT2AMEN1CYP1A2CYP2C19KDM4E
SCHEMBL30212531 0.81 NPC1 (0.57) KMT2AMEN1CYP1A2CYP2C19KDM4E
SCHEMBL46317 0.77 KDM4E (0.58) KMT2AMEN1CYP1A2CYP2C19KDM4E
SCHEMBL24921496 0.77 NPC1 (0.42) KMT2AMEN1CYP1A2CYP2C19KDM4E
SCHEMBL31516755 0.77 KDM4E (0.58) KMT2AMEN1CYP1A2CYP2C19KDM4E
SCHEMBL12989738 0.77 LMNA (0.50) KMT2AMEN1CYP1A2CYP2C19LMNA
SCHEMBL24920394 0.77 NPC1 (0.49) KMT2AMEN1CYP1A2CYP2C19KDM4E
SCHEMBL12706294 0.76 LMNA (0.49) KMT2AMEN1CYP1A2CYP2C19KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1910171-A Method for preparation of 6-11 bicyclo erythromycin derivant ENNATA PHARMACEUTICALS INC (US) 2007-02-07 CN claimed
WO-2023006097-A1 BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER 海创药业股份有限公司 2023-02-02 WO disclosed
US-9149465-B2 Isoxazolines as inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-10-06 US disclosed
US-8927551-B2 Isoxazolines as inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-01-06 US disclosed
US-8765735-B2 Isoxazolines as inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2014-07-01 US disclosed